每經AI快訊，8月13日，歌禮制藥(yao)在(zai)港交所(suo)公告，公司(si)董(dong)事(shi)會宣布(bu)，同類首創的治療肥(fei)(fei)胖(pang)癥的減(jian)(jian)重(zhong)不(bu)減(jian)(jian)肌候選藥(yao)物(wu)ASC47與(yu)(yu)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)聯(lian)用(yong)(yong)(yong)在(zai)飲(yin)食誘(you)導(dao)肥(fei)(fei)胖(pang)(DIO)小(xiao)鼠(shu)(shu)(shu)研究中(zhong)顯(xian)示出令人(ren)鼓(gu)舞的療效(xiao)結果。在(zai)飲(yin)食誘(you)導(dao)肥(fei)(fei)胖(pang)(DIO)小(xiao)鼠(shu)(shu)(shu)中(zhong)，低(di)劑(ji)(ji)量ASC47與(yu)(yu)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)聯(lian)用(yong)(yong)(yong)比(bi)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)單(dan)藥(yao)療法(fa)多減(jian)(jian)重(zhong)87%。在(zai)DIO小(xiao)鼠(shu)(shu)(shu)模(mo)型中(zhong)，低(di)劑(ji)(ji)量ASC47與(yu)(yu)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)聯(lian)用(yong)(yong)(yong)對比(bi)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)單(dan)藥(yao)多減(jian)(jian)重(zhong)87%，ASC47與(yu)(yu)司(si)美格魯肽(tai)(tai)聯(lian)用(yong)(yong)(yong)對比(bi)司(si)美格魯肽(tai)(tai)單(dan)藥(yao)多減(jian)(jian)重(zhong)55%，與(yu)(yu)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)聯(lian)用(yong)(yong)(yong)減(jian)(jian)重(zhong)效(xiao)果更好，具有統計(ji)學顯(xian)著性。低(di)劑(ji)(ji)量ASC47與(yu)(yu)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)聯(lian)用(yong)(yong)(yong)使肥(fei)(fei)胖(pang)小(xiao)鼠(shu)(shu)(shu)身體成(cheng)分(fen)恢復至健康非(fei)肥(fei)(fei)胖(pang)小(xiao)鼠(shu)(shu)(shu)的水平。治療結束時，經低(di)劑(ji)(ji)量ASC47與(yu)(yu)替爾(er)(er)(er)泊(bo)(bo)肽(tai)(tai)聯(lian)用(yong)(yong)(yong)治療的肥(fei)(fei)胖(pang)小(xiao)鼠(shu)(shu)(shu)的總肌肉量占總體重(zhong)的百分(fen)比(bi)(60.4%)與(yu)(yu)健康非(fei)肥(fei)(fei)胖(pang)小(xiao)鼠(shu)(shu)(shu)(62.0%)相當。